Similar Search Results

Benefit assessment in Germany : implications for price discounts

Theidel, Ulrike; Schulenburg, Johann-Matthias von der - In: Health economics review 6 (2016) 33, pp. 1-12

-SV takes place behind closed doors, the factors influencing the results of the negotiation are not known. Objectives: The aim … of this evaluation is to identify factors influencing the results of the AMNOG price negotiation process. Methods: The …, the outcome of the discount negotiations are still unpredictable. Obviously, negotiation tactics, the current political …

Persistent link: https://www.econbiz.de/10011586599

Who is Best at Negotiating Pharmaceutical Rebates?

Abrams, Lawrence W. - 2011

Persistent link: https://www.econbiz.de/10013128092

Who is Best at Negotiating Pharmaceutical Rebates?

Abrams, Lawrence - 2016

The roll out of the new Medicare drug benefit program has renewed the debate about who is best at negotiating drug rebates with pharmaceutical manufacturers (“Pharma”). Those who favor the Federal government point to statistics showing that Medicaid gets significantly better rebates than...

Persistent link: https://www.econbiz.de/10014125027

Medikamenten Monopoly : die unheilvolle Welt der Arzneimittelgeschäfte

Stadler, Franz - 2020

Seit 30 Jahren erlebt der Apotheker und promovierte Pharmazeut Franz Stadler alle Tricks und Betrügereien der Arzneimittelindustrie. Als Experte und Insider packt er jetzt aus und seziert messerscharf diese Geschäfte, ihre Player und die Geldflüsse dahinter. Heraus kommt ein komplexes System,...

Persistent link: https://www.econbiz.de/10012291152

Parallel imports and manufacturer rebates : evidence from Germany

Birg, Laura - 2019

pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …In this paper, I study the effect of a change in the mandatory manufacturer rebate on wholesale prices for … imports in a two-country model. An increase in the manufacturer rebate increases the market share of parallel imports. Second …

Persistent link: https://www.econbiz.de/10011949028

Parallel imports under a manufacturer rebate and a price freeze : evidence from Germany

Birg, Laura - In: Health economics 32 (2023) 2, pp. 302-323

Persistent link: https://www.econbiz.de/10014266802

Bargaining power and quantity discounts to retailers : evidence from India's pharmaceutical industry

Antonecchia, Gianluca; Bhaskarabhatla, Ajay; Pennings, … - 2024

This paper develops a novel theory linking quantity discounts to bargaining power in scenarios where retailers, organized as a trade association, negotiate uniform wholesale prices with suppliers. Our theory predicts that suppliers offer greater quantity discounts in regional markets where they...

Persistent link: https://www.econbiz.de/10014583242

Government procurement defence under GATT 1994 Article III.8(a) : a critical review of the Turkey-Pharmaceutical Products Dispute

Yun, Mikyung - In: Journal of world trade : law, economic policy, public policy 57 (2023) 1, pp. 183-207

Persistent link: https://www.econbiz.de/10014283837

Reciprocity, Harmonisation and Mutual and Mutual Recognition of Regulatory Measures: A Political Economy Perspective

Suwa-Eisenmann, Akiko; Verdier, Thierry - Laboratoire d'Economie Appliquee, INRA

This paper discusses the issue of regulatory protectionism and its implication for reciprocity and international bargaining on regulation. In a simple two way trade model a la Brander and Spencer, we take into account the three following features of regulatory measures: a) a regulation raises...

Persistent link: https://www.econbiz.de/10005027409

Income-based price subsidies, parallel imports and markets access to new drugs for the poor

Acharyya, Rajat; García-Alonso, María D. C. - 2008

In health markets, government policies tend to subsidize poorer groups. The purpose of this paper is to analyze the implications of an income-based subsidy policy on the incentives of countries to implement price arbitrage and of firms to provide market access to poorer groups.

Persistent link: https://www.econbiz.de/10010277840

1
2
3
4
5
6
7
8
9
10
Next
Last